Peter Harrison, Chief Executive of Bioventix PLC, joins Victoria Stevens for the latest episode of Stock Exchanges to discuss building a highly profitable biotechnology business from a management buyout over two decades ago.

Peter explains how he transformed a failing therapeutic antibody company into a diagnostics business, why sheep monoclonal antibodies offer advantages over traditional mouse antibodies for blood tests, and how Bioventix is contributing to research efforts in early Alzheimer's detection through biomarker development.